Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatocellular Cancer
Reports summarize hepatocellular cancer research from N. Murakami and co-authors
May 21st, 2008
"Des-gamma-carboxy prothrombin (DCP) is measured by an enzyme immunoassay system with the monoclonal antibody MU-3. A novel DCP antibody named 19137 recognizes a different epitope against the Gla domain of DCP measured by the MU-3 antibody," researchers in Mibu, Japan report. "Therefore, it is possible that DCP variants can be measured with these two antibodies. The aim of this study was to elucidate the usefulness of the DCP ratio as a new prognostic parameter for patients with hepatocellular carcinoma (HCC). One hundred and eighty-three patients with HCC were enrolled in the current study. The DCP ratio was calculated using the formula: DCP ratio = DCP level measured...
Source: Immunotherapy Weekly (2008-05-21)
|
